Publicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario de Pontevedra (24)

2026

  1. Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort

    Journal of the International AIDS Society, Vol. 29, Núm. 4

  2. Influence of the level of education on cognitive function in Parkinson’s disease

    Journal of Neural Transmission, Vol. 133, Núm. 4, pp. 663-681

  3. Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort

    HIV Medicine, Vol. 27, Núm. 5, pp. 690-709

  4. Predictive Factors and Impact of Significant Weight Loss on Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study

    Movement Disorders Clinical Practice

  5. Profile of People With Parkinson's Disease Treated With a Device-Aided Therapy in Spain. A Comparative Multicenter Observational Study

    Movement Disorders Clinical Practice, Vol. 13, Núm. 1, pp. 154-172

  6. Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study

    American Journal of Hematology

  7. Safety of sonidegib in elderly patients with locally advanced basal cell carcinoma: A multicentre study

    Journal of the European Academy of Dermatology and Venereology

2025

  1. A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)

    Journal of Antimicrobial Chemotherapy, Vol. 80, Núm. 12, pp. 3438-3451

  2. Correction to: Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline (Journal of Neurology, (2025), 272, 3, (246), 10.1007/s00415-024-12808-0)

    Journal of Neurology

  3. Device-aided therapies (DATs) in Parkinson's disease (PD). The DATs-PD GETM Spanish Registry Protocol Study

    PLoS ONE, Vol. 20, Núm. 3 March

  4. Dysphagia in Parkinson´s disease. A 5-year follow-up study

    Neurological Sciences, Vol. 46, Núm. 6, pp. 2637-2653

  5. Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline

    Journal of Neurology, Vol. 272, Núm. 3

  6. Impact of device-aided therapies on quality of life in patients with Parkinson’s disease. A comparative multicenter observational study

    Journal of Neural Transmission

  7. Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study)

    Cancers, Vol. 17, Núm. 22

  8. Response to Sonidegib in Advanced Basal Cell Carcinomas by Histological Subtype: A Real-World Cohort

    International Journal of Dermatology

  9. Sex differences in treatment strategies for pulmonary embolism in older adults: The SERIOUS-PE study of RIETE participants and US Medicare beneficiaries

    Vascular Medicine (United Kingdom), Vol. 30, Núm. 1, pp. 58-66

  10. Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO

    Blood Advances, Vol. 9, Núm. 19, pp. 4924-4935

  11. Venous thromboembolism in patients aged ≥90 years: Trends in clinical features, treatment, and outcomes—RIETE registry

    Journal of the American Geriatrics Society, Vol. 73, Núm. 4, pp. 1219-1226

2024

  1. Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study

    Movement Disorders Clinical Practice, Vol. 11, Núm. 7, pp. 830-849

  2. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597